A N Chirkov studies ischemic stroke, which occurs when a blood vessel supplying blood to the brain is blocked. They are particularly focused on a treatment called Revelise, which helps dissolve the blockage and restore blood flow. Their research involves assessing how well this medication works for patients, especially those who are older or have other health conditions, helping doctors understand how to improve patient outcomes in these situations.
Key findings
In the International PRIMA Study, 49.9% of the 2,202 patients treated with Revelise had good outcomes upon discharge.
After 90 days, the percentage of patients with favorable results increased to 66.4%.
The study demonstrated that Revelise significantly reduces stroke-related disabilities in patients, even among older individuals and those with other health issues.
Frequently asked questions
Does Dr. Chirkov study ischemic stroke?
Yes, Dr. Chirkov focuses on ischemic stroke and treatments to improve patient outcomes.
What treatment has Dr. Chirkov researched?
Dr. Chirkov has researched the medication Revelise for treating ischemic stroke.
Is Dr. Chirkov's work relevant to older stroke patients?
Yes, their research specifically includes older patients and shows that Revelise is effective for them.
Publications in plain English
[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more
Plain English This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options.
Who this helps: Patients with acute ischemic stroke and their healthcare providers.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].
2022
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Gusev EI, Martynov MY, Shamalov NA, Yarovaya EB, Semenov MP +36 more
Plain English This study compared two treatments for patients suffering from acute ischemic stroke: non-immunogenic staphylokinase (NS) and alteplase (A). Out of 336 patients, 50% of those who received NS had a good recovery after 90 days, while 41% of those who received alteplase did, showing that NS may be a more effective option. It also resulted in fewer serious complications, with 13% of NS patients experiencing significant side effects compared to 22% in the alteplase group.
Who this helps: This helps patients who are dealing with acute ischemic strokes.
[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
2022
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Soldatov MA, Klimov LV, Tolmachev AP, Kiseleva TV, Androfagina OV +17 more
Plain English This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days.
Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.
[Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
2021
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Soldatov MA, Marskaya NA, Barsegova KA, Androfagina OV, Borisov DN +9 more
Plain English This study looked at the use of a drug called Revelisa for treating ischemic stroke patients in real-life hospital settings. Out of 223 patients treated, 7.1% experienced complications from bleeding in the brain, and 13.9% died during their hospital stay. After treatment, nearly half of the patients (48.2%) showed good recovery at discharge, which is comparable to results from other treatments like alteplase.
Who this helps: Patients who suffer from ischemic strokes.
[Algorithms of the correction of fluid and electrolyte disorders in patients with severe ischemic stroke].
2017
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Ershov VI, Chirkov AN
Plain English This study looked at how to manage sodium levels in patients who have had a severe ischemic stroke. Researchers analyzed 150 patients who were admitted within the first 12 hours of their stroke and found that low sodium levels (hyponatremia) do not directly predict recovery outcomes, but need to be diagnosed and corrected. For high sodium levels (hypernatremia), a gradual correction plan was safe to follow initially, but if levels exceeded certain thresholds, quicker treatment was necessary.
Who this helps: This information benefits patients who have suffered a severe stroke and their doctors, guiding immediate treatment for electrolyte imbalances.
[Hypovolemic hyponatremia at the onset of severe ischemic stroke as a predictor of adverse outcome].
2016
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Ershov VI, Chirkov AN
Plain English This study looked at how changes in water and salt levels in the body right after a severe stroke can predict a patient's recovery. Researchers found that patients with low blood sodium levels (hyponatremia) and high plasma osmolarity on the first day of their stroke were more likely to have a poor outcome. Specifically, a sodium level above 155 mEq/L or osmolarity above 297 mOsmol/L increased the risk of complications. This matters because it helps identify which patients might be at higher risk after a severe stroke, allowing for more timely and targeted care.
Who this helps: This helps doctors better assess and treat patients who have suffered a severe stroke.
PROGNOSTIC SIGNIFICANCE OF WATER AND ELECTROLYTE DISORDERS IN THE ACUTE PERIOD OF SEVERE ISCHEMIC STROKE.
2016
Anesteziologiia i reanimatologiia
Chirkov AN, Ershov VI
Plain English This study looked at how the level of substances in the blood affects the outcomes of patients suffering from severe ischemic stroke, a type of stroke caused by blocked blood flow. Researchers found that a blood plasma osmolarity level of 297 mOsm/L on the first day of the stroke is linked to a poor prognosis, especially for patients with the cardioembolic subtype of stroke, which generally has a more severe course and worse outcomes. Understanding these levels helps predict which patients are more likely to have serious complications after a stroke.
Who this helps: This benefits patients with ischemic stroke and their doctors by providing insights for better management and treatment strategies.